{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:26:34Z","timestamp":1794288394573,"version":"4.9.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006636","name":"University of Maryland, Baltimore County","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1114766"],"award-info":[{"award-number":["OPP1114766"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2023.09.040","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:25:49Z","timestamp":1695936349000},"page":"7047-7059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7\u20138, 2022"],"prefix":"10.1016","volume":"41","author":[{"given":"Meagan C.","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Feikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonnie","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaly","family":"Koltai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Pecenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmini","family":"Srikantiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-5965","authenticated-orcid":false,"given":"Justin R.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.09.040_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.02.040","article-title":"WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use","author":"Sparrow","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0010","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1016\/j.vaccine.2017.09.092","article-title":"Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.09.081","article-title":"Value profile for respiratory syncytial virus vaccines and monoclonal antibodies","author":"Fleming","year":"2023","journal-title":"Vaccine"},{"issue":"91","key":"10.1016\/j.vaccine.2023.09.040_b0020","first-page":"266","article-title":"conclusions and recommendations","volume":"2016","author":"Meeting of the Strategic Advisory Group of Experts on immunization","year":"2016","journal-title":"Weekly Epidemiological Record"},{"key":"10.1016\/j.vaccine.2023.09.040_b0025","doi-asserted-by":"crossref","first-page":"e1031","DOI":"10.1016\/S2214-109X(19)30264-5","article-title":"Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis","volume":"7","author":"Li","year":"2019","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0030","unstructured":"Centers for Disease Control and Prevention. RSV in Infants and Young Children. 2020."},{"key":"10.1016\/j.vaccine.2023.09.040_b0035","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.040_b0040","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0105-2022","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries","volume":"31","author":"Nguyen-Van-Tam","year":"2022","journal-title":"European Respiratory Review"},{"key":"10.1016\/j.vaccine.2023.09.040_b0045","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of reinfection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3389\/fimmu.2019.01006","article-title":"Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade","volume":"10","author":"Aranda","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.vaccine.2023.09.040_b0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","article-title":"Immunological Lessons from Respiratory Syncytial Virus Vaccine Development","volume":"51","author":"Ruckwardt","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2023.09.040_b0060","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Bronchiolitis Guidelines Committee, Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","author":"American Academy of Pediatrics Committee on Infectious Diseases","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.09.040_b0065","unstructured":"PATH. RSV Vaccine and mAb Snapshot. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b0070","unstructured":"European Medicines Agency. Beyfortus 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b9000","unstructured":"FDA News Release: FDA Approves New Drug to Prevent RSV in Babies and Toddlers, 17 July 2023. Available here: https:\/\/fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers (accessed on 22 September 2023)."},{"key":"10.1016\/j.vaccine.2023.09.040_b0075","unstructured":"Pfizer. U.S. FDA Accepts Biologics License Application for Pfizer\u2019s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b9005","unstructured":"European Medicines Agency, Abrysvo, Respiratory syncytial virus vaccines, available here: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo (accessed on 22 September 2023) (note this covers the older adult and maternal vaccine)."},{"key":"10.1016\/j.vaccine.2023.09.040_b0080","unstructured":"Food and Drug Agency. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b9010","unstructured":"FDA News Release, FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in infants, 21 August 2023, available here: https:\/\/fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants (accessed on 22 September 2023)."},{"key":"10.1016\/j.vaccine.2023.09.040_b0085","unstructured":"World Health Organization. Guidance for the Development of Evidence-based Vaccination-related Recommendations. 2017."},{"key":"10.1016\/j.vaccine.2023.09.040_b0090","unstructured":"Gavi The Vaccine Alliance. Vaccine investment strategy. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0095","doi-asserted-by":"crossref","unstructured":"Bertram MY, Edejer TTT. Introduction to the Special Issue on \u201cThe World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update\u201d. Int J Health Policy Manag. 2021;10:670-2.","DOI":"10.34172\/ijhpm.2021.105"},{"key":"10.1016\/j.vaccine.2023.09.040_b0100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.040_b0105","doi-asserted-by":"crossref","first-page":"e2237689","DOI":"10.1001\/jamanetworkopen.2022.37689","article-title":"Prioritizing Health Care Strategies to Reduce Childhood Mortality","volume":"5","author":"Madewell","year":"2022","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.vaccine.2023.09.040_b0110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(18)31127-9","article-title":"Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study","volume":"392","author":"Saha","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.040_b0125","unstructured":"Nair H. Global, regional and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015, 1995-2015. In: Edinburgh Uo, editor.: Usher Institute of Population Health Sciences and Informatics; 2016."},{"key":"10.1016\/j.vaccine.2023.09.040_b0130","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study","volume":"394","author":"Pneumonia Etiology Research for Child Health Study Group","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.040_b0135","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1473-3099(15)00247-9","article-title":"Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial","volume":"15","author":"O'Brien","year":"2015","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0140","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD 2016 Lower Respiratory Infections Collaborators","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0145","unstructured":"PATH. RSV Clinical Trial Tracker. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0150","unstructured":"Food and Drug Agency. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b0155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/bmj.p1187","article-title":"FDA advisers back Pfizer's maternal RSV vaccine after voicing safety concerns","volume":"381","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.09.040_b0160","unstructured":"Food and Drug Agency. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b0165","unstructured":"Pfizer. European Commission Approves Pfizer\u2019s ABRYSVO\u2122 to Help Protect Infants through Maternal Immunization and Older Adults from RSV. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b0170","first-page":"9","article-title":"Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities","author":"Ananworanich","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.09.040_b0175","unstructured":"Medicines & Healthcare products Regluatory Agency. Decision Cover Letter. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0180","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1056\/NEJMc2112186","article-title":"Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity","volume":"386","author":"Domachowske","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0185","unstructured":"Clinicaltrials.gov. A phase 2B placebo-controlled, randomized study of a respiratory syncytial virus (RSV) vaccine in pregnant women. 2023."},{"key":"10.1016\/j.vaccine.2023.09.040_b0190","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1016\/j.vaccine.2020.05.084","article-title":"Vaccine implementation factors affecting maternal tetanus immunization in low- and middle-income countries: Results of the Maternal Immunization and Antenatal Care Situational Analysis (MIACSA) project","volume":"38","author":"Giles","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0195","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0200","unstructured":"World Health Organization. WHO and UNICEF estimates of national immunization coverage: 2019 revision. 2019."},{"key":"10.1016\/j.vaccine.2023.09.040_b0205","unstructured":"UNICEF. Antenatal care. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0210","doi-asserted-by":"crossref","first-page":"e0237718","DOI":"10.1371\/journal.pone.0237718","article-title":"Inferring antenatal care visit timing in low- and middle-income countries: Methods to inform potential maternal vaccine coverage","volume":"15","author":"Baral","year":"2020","journal-title":"PLoS One1"},{"key":"10.1016\/j.vaccine.2023.09.040_b0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12916-020-01537-6","article-title":"Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries","volume":"18","author":"Li","year":"2020","journal-title":"BMC Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0220","doi-asserted-by":"crossref","first-page":"e046563","DOI":"10.1136\/bmjopen-2020-046563","article-title":"Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model","volume":"11","author":"Baral","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.09.040_b0225","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.vaccine.2021.06.086","article-title":"Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions","volume":"39","author":"Laufer","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0230","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12916-023-02806-w","article-title":"Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa","volume":"21","author":"Koltai","year":"2023","journal-title":"BMC Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0235","unstructured":"York Health Economics Consortium. Expected Value of Partially Perfect Information (EVPPI). York2016."},{"key":"10.1016\/j.vaccine.2023.09.040_b0240","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.06.010408","article-title":"Cost of management of severe pneumonia in young children: systematic analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"Journal of Global Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0245","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jpids\/piaa157","article-title":"Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi","volume":"9","author":"Baral","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2023.09.040_b0250","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0009922819843639","article-title":"Impact of Respiratory Syncytial Virus-Confirmed Hospitalizations on Caregivers of US Preterm Infants","volume":"58","author":"Pokrzywinski","year":"2019","journal-title":"Clinical Pediatrics (Phila)"},{"key":"10.1016\/j.vaccine.2023.09.040_b0255","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S2213-2600(20)30109-0","article-title":"Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis","volume":"8","author":"Brunwasser","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0260","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/cid\/ciaa403","article-title":"Community-Based Antibiotic Prescribing Attributable to Respiratory Syncytial Virus and Other Common Respiratory Viruses in Young Children: A Population-Based Time-series Study of Scottish Children","volume":"72","author":"Fitzpatrick","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0265","unstructured":"Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet (London, England). 2019;394:757-79."},{"key":"10.1016\/j.vaccine.2023.09.040_b0270","article-title":"Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: A systematic review and meta-analysis","volume":"5","author":"Shi","year":"2015","journal-title":"Journal of Global Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0275","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1093\/cid\/ciab509","article-title":"Deaths Attributed to Respiratory Syncytial Virus in Young Children in High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS)","volume":"73","author":"Blau","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0280","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2214-109X(21)00518-0","article-title":"Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project","volume":"10","author":"Gill","year":"2022","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0285","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciab481","article-title":"Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: A Prospective Community Cohort Study in Rural Maharashtra, India","volume":"73","author":"Sim\u00f5es","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0290","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1093\/cid\/ciab488","article-title":"Respiratory Syncytial Virus-Associated Mortality Among Young Infants in Karachi, Pakistan: A Prospective Postmortem Surveillance Study","volume":"73","author":"Kazi","year":"2021","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2023.09.040_b0295","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(13)61682-7","article-title":"Use of vaccines as probes to define disease burden","volume":"383","author":"Feikin","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.09.040_b0300","unstructured":"UNICEF. Vaccines pricing data. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0305","unstructured":"World Health Organization. MI4A Vaccine Purchase Database. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0310","unstructured":"Immunizationeconomics.org. Immunization Delivery Cost Catalogue. 2022."},{"key":"10.1016\/j.vaccine.2023.09.040_b0315","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1016\/j.vaccine.2020.07.050","article-title":"A review of the costs of delivering maternal immunisation during pregnancy","volume":"38","author":"Procter","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0320","first-page":"673","article-title":"Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICE","volume":"10","author":"Bertram","year":"2021","journal-title":"International Journal of Health Policy and Management"},{"key":"10.1016\/j.vaccine.2023.09.040_b0325","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1016\/j.vaccine.2023.09.040_b0330","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-1-8","article-title":"Generalized cost-effectiveness analysis for national-level priority-setting in the health sector","volume":"1","author":"Hutubessy","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vaccine.2023.09.040_b0335","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"Ochalek","year":"2018","journal-title":"BMJ Global Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0340","doi-asserted-by":"crossref","first-page":"e0001432","DOI":"10.1371\/journal.pgph.0001432","article-title":"Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis","volume":"3","author":"Laufer","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.vaccine.2023.09.040_b0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhealeco.2018.02.003","article-title":"Allocation rules for global donors","volume":"58","author":"Morton","year":"2018","journal-title":"Journal of Health Economics"},{"key":"10.1016\/j.vaccine.2023.09.040_b0350","unstructured":"World Health Organization. Haemophilus influenzae type b (Hib) meningitis in the pre-vaccine era : a global review of incidence, age distributions, and case-fatality rates. 2002."},{"key":"10.1016\/j.vaccine.2023.09.040_b0355","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants","volume":"383","author":"Madhi","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2023.09.040_b0360","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1016\/j.vaccine.2020.06.036","article-title":"The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models","volume":"38","author":"Baral","year":"2020","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23011106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:09:24Z","timestamp":1720037364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23011106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":75,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0264410X23011106"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.040","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7\u20138, 2022","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}